JP2012509892A - サティオゲン類を含有する組成物及び使用の方法 - Google Patents

サティオゲン類を含有する組成物及び使用の方法 Download PDF

Info

Publication number
JP2012509892A
JP2012509892A JP2011537692A JP2011537692A JP2012509892A JP 2012509892 A JP2012509892 A JP 2012509892A JP 2011537692 A JP2011537692 A JP 2011537692A JP 2011537692 A JP2011537692 A JP 2011537692A JP 2012509892 A JP2012509892 A JP 2012509892A
Authority
JP
Japan
Prior art keywords
peptide
secretagogue
certain embodiments
bile
rectal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011537692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509892A5 (https=
Inventor
エー． ヤング，アンドリュー
ゲドリン，ブロニスラヴァ
グリーン，ハワード，イー．
Original Assignee
サティオゲン ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サティオゲン ファーマシューティカルズ，インク． filed Critical サティオゲン ファーマシューティカルズ，インク．
Publication of JP2012509892A publication Critical patent/JP2012509892A/ja
Publication of JP2012509892A5 publication Critical patent/JP2012509892A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011537692A 2008-11-26 2009-11-23 サティオゲン類を含有する組成物及び使用の方法 Pending JP2012509892A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11832408P 2008-11-26 2008-11-26
US61/118,324 2008-11-26
US25521109P 2009-10-27 2009-10-27
US61/255,211 2009-10-27
PCT/US2009/065587 WO2010062863A2 (en) 2008-11-26 2009-11-23 Compositions containing satiogens and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014004971A Division JP2014062134A (ja) 2008-11-26 2014-01-15 サティオゲン類を含有する組成物

Publications (2)

Publication Number Publication Date
JP2012509892A true JP2012509892A (ja) 2012-04-26
JP2012509892A5 JP2012509892A5 (https=) 2013-01-17

Family

ID=41572705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011537692A Pending JP2012509892A (ja) 2008-11-26 2009-11-23 サティオゲン類を含有する組成物及び使用の方法
JP2014004971A Pending JP2014062134A (ja) 2008-11-26 2014-01-15 サティオゲン類を含有する組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014004971A Pending JP2014062134A (ja) 2008-11-26 2014-01-15 サティオゲン類を含有する組成物

Country Status (7)

Country Link
US (3) US8318663B2 (https=)
EP (1) EP2364161B1 (https=)
JP (2) JP2012509892A (https=)
CN (1) CN102316889B (https=)
CA (1) CA2744697C (https=)
GB (1) GB2465677B (https=)
WO (1) WO2010062863A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501158A (ja) * 2013-12-18 2017-01-12 ティラビスコ アーベー 嗜好性食品に対する衝動を減らすためのチラコイドの使用
WO2017170854A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 有効成分の化学的安定性に優れたフィルムコーティング錠
WO2017170858A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
JP2022544239A (ja) * 2019-08-12 2022-10-17 マサチューセッツ インスティテュート オブ テクノロジー 治療薬の投与のための物品及び方法

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JP2012509892A (ja) 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． サティオゲン類を含有する組成物及び使用の方法
CA2744817C (en) * 2008-11-26 2020-07-07 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
RS56054B1 (sr) * 2009-01-12 2017-09-29 Biokier Inc Smeša i metod za lečenje dijabetesa
CN102711800A (zh) 2009-09-23 2012-10-03 拜奥基尔公司 治疗糖尿病的组合物和方法
US20110086829A1 (en) * 2009-10-09 2011-04-14 Zadini Filiberto P Compositions and methods for treating obesity
US20110152204A1 (en) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of Obesity or Diabetes with Bile Acid Sequestrants
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2010359050B2 (en) 2010-08-12 2016-03-17 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
CN103702668A (zh) * 2011-05-02 2014-04-02 拜奥基尔公司 治疗糖尿病的组合物和方法
CA2842707A1 (en) * 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pancreatitis
US11154559B2 (en) * 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
US9402968B2 (en) 2012-07-11 2016-08-02 Mercy Medical Research Institute, Inc. Colorectal delivery device
CN104644591A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 一种沙格列汀药物组合物及其制备方法
KR101812530B1 (ko) * 2014-02-12 2017-12-27 야마하하쓰도키 가부시키가이샤 촬영 장치, 차량 및 화상 보정 방법
ES2929516T3 (es) * 2014-10-31 2022-11-29 Univ Utah Res Found Composiciones y métodos para partículas con ácidos biliares
ES2688119T3 (es) * 2015-07-08 2018-10-31 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento de cambios inflamatorios del recto
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
WO2020117945A1 (en) 2018-12-04 2020-06-11 President And Fellows Of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
JP2020186223A (ja) * 2019-05-09 2020-11-19 救心製薬株式会社 牛黄及び／又は鹿茸及び／又は胆汁酸を含有する組成物
AU2020274319B2 (en) 2019-05-10 2026-02-12 President And Fellows Of Harvard College Small molecule modulators of gut bacterial bile acid metabolism
CN110314167A (zh) * 2019-07-04 2019-10-11 北京大学第三医院（北京大学第三临床医学院） 胆汁酸作为制备治疗pcos药物的应用及药物制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6396138A (ja) * 1986-10-07 1988-04-27 エフ・ホフマン―ラ　ロシユ　アーゲー 製薬学的組成物
JP2008513465A (ja) * 2004-09-15 2008-05-01 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ 肥満及び糖尿病の治療におけるｅｒストレス低減

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245890B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
US5415872A (en) 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
KR970005178B1 (ko) 1993-12-28 1997-04-14 이승철 피로회복제 조성물
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
US6060465A (en) * 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
AU766219B2 (en) 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
JP2000026300A (ja) 1998-07-02 2000-01-25 Pola Chem Ind Inc 血管内皮細胞保護医薬組成物
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
PT1741446E (pt) * 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
WO2001077325A1 (fr) 2000-04-12 2001-10-18 Takeda Chemical Industries, Ltd. Nouvelle proteine de recepteur couple aux proteines g et adn de celle-ci
US6451355B1 (en) * 2000-07-17 2002-09-17 Howard M. Reisner Composition to treat diabetes
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
US7198914B2 (en) 2000-11-17 2007-04-03 Banyu Pharmaceutical Co., Ltd. Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37
JP2005531570A (ja) 2002-05-23 2005-10-20 ユーエムディー， インコーポレイテッド 貫粘膜薬物送達及び凍結保護のための組成物及び方法
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
JP2005097216A (ja) * 2003-09-26 2005-04-14 Kaneka Corp ＰＰＡＲγリガンド剤
CA2588168A1 (en) 2004-11-24 2006-06-01 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20060193895A1 (en) * 2005-02-25 2006-08-31 Use-Techno Corporation Additive for food and beverage, pharmaceutical composition, GLUT4 translocator, and method for translocating GLUT4
FR2883284A1 (fr) 2005-03-15 2006-09-22 Commissariat Energie Atomique Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
US20080031968A1 (en) * 2005-04-01 2008-02-07 The Brigham And Women's Hospital, Inc. Methods for increasing cellular energy expenditure
WO2006116814A1 (en) 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition and uses thereof
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
PE20110235A1 (es) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7932244B2 (en) 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
JP2010509252A (ja) 2006-11-14 2010-03-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 改善された特性を有する新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
KR101555716B1 (ko) 2007-01-19 2015-09-25 인터셉트 파마슈티컬즈, 인크. Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
DK2698375T3 (en) 2008-11-19 2018-05-28 Intercept Pharmaceuticals Inc TGR5 modulators and methods for using them
JP2012509892A (ja) 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． サティオゲン類を含有する組成物及び使用の方法
RS56054B1 (sr) * 2009-01-12 2017-09-29 Biokier Inc Smeša i metod za lečenje dijabetesa
CN102711800A (zh) 2009-09-23 2012-10-03 拜奥基尔公司 治疗糖尿病的组合物和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6396138A (ja) * 1986-10-07 1988-04-27 エフ・ホフマン―ラ　ロシユ　アーゲー 製薬学的組成物
JP2008513465A (ja) * 2004-09-15 2008-05-01 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ 肥満及び糖尿病の治療におけるｅｒストレス低減

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6013002670; 渡辺光博: Ｆｕｎｃｔｉｏｎａｌ　Ｆｏｏｄ Ｖｏｌ．２，　Ｎｏ．１, 200804, ｐ．５７-６３ *
JPN6013002673; ＨＯＳＮＹ，　Ｅ．Ａ．　ｅｔ　ａｌ．: Ｄｒｕｇ　Ｄｅｖｅｌｏｐｍｅｎｔ　ａｎｄ　Ｉｎｄｕｓｔｒｉａｌ　Ｐｈａｒｍａｃｙ Ｖｏｌ．２７，　Ｎｏ．８, 2001, ｐ．８３７-８４５ *
JPN6013002675; ＫＡＴＳＵＭＡ，　Ｓ．　ｅｔ　ａｌ．: Ｂｉｏｃｈｅｍｉｃａｌ　ａｎｄ　Ｂｉｏｐｈｙｓｉｃａｌ　Ｒｅｓｅａｒｃｈ　Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．３２９, 2005, ｐ．３８６-３９０ *
JPN6013002677; ＤＵＭＯＵＬＩＮ，　Ｖ．　ｅｔ　ａｌ．: Ｅｎｄｏｃｒｉｎｏｌｏｇｙ Ｖｏｌ．１３９，　Ｎｏ．９, 1998, ｐ．３７８０-３７８６ *
JPN6013002680; ＡＤＲＩＡＮ，　Ｔ．Ｅ．　ｅｔ　ａｌ．: Ｇｕｔ． Ｖｏｌ．３４, 1993, ｐ．１２１９-１２２４ *
JPN6013002682; ＲＥＩＭＡＮＮ，　Ｆ．　ｅｔ　ａｌ．: ＤＩＡＢＥＴＥＳ Ｖｏｌ．５５，　Ｓｕｐｐｌ．２, 2006, Ｓ７８-Ｓ８５ *
JPN6013002684; 難波光義ら: 日本消化器学会雑誌 Ｖｏｌ．１０２，　Ｎｏ．１１, 2005, ｐ．１３９８-１４０４ *
JPN6013002686; ＢＡＬＡＳ，　Ｂ．　ｅｔ　ａｌ．: Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｅｎｄｏｃｒｉｎｏｌｏｇｙ　＆　Ｍｅｔａｂｏｌｉｓｍ Ｖｏｌ．９２，　Ｎｏ．４, 2007, ｐ．１２４９-１２５５ *
JPN6013002687; ＲＡＵＮ，　Ｋ．　ｅｔ　ａｌ．: ＤＩＡＢＥＴＥＳ Ｖｏｌ．５６, 2007, ｐ．８-１５ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501158A (ja) * 2013-12-18 2017-01-12 ティラビスコ アーベー 嗜好性食品に対する衝動を減らすためのチラコイドの使用
WO2017170854A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 有効成分の化学的安定性に優れたフィルムコーティング錠
WO2017170858A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
JPWO2017170858A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
JPWO2017170854A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 有効成分の化学的安定性に優れたフィルムコーティング錠
JP2022544239A (ja) * 2019-08-12 2022-10-17 マサチューセッツ インスティテュート オブ テクノロジー 治療薬の投与のための物品及び方法

Also Published As

Publication number Publication date
US20130190281A1 (en) 2013-07-25
US20100130426A1 (en) 2010-05-27
GB2465677A (en) 2010-06-02
US8318663B2 (en) 2012-11-27
EP2364161A4 (en) 2012-12-26
EP2364161B1 (en) 2020-03-11
CN102316889B (zh) 2014-11-26
GB2465677B (en) 2012-09-26
GB0920703D0 (en) 2010-01-13
CA2744697A1 (en) 2010-06-03
US10028952B2 (en) 2018-07-24
CN102316889A (zh) 2012-01-11
WO2010062863A2 (en) 2010-06-03
EP2364161A2 (en) 2011-09-14
WO2010062863A3 (en) 2010-09-23
US20160235745A1 (en) 2016-08-18
CA2744697C (en) 2016-06-21
JP2014062134A (ja) 2014-04-10
US9345715B2 (en) 2016-05-24

Similar Documents

Publication Publication Date Title
US10028952B2 (en) Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof
US20220362238A1 (en) Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US20130034536A1 (en) Bile Acid Recycling Inhibitors for Treatment of Pancreatitis
US20110152204A1 (en) Treatment of Obesity or Diabetes with Bile Acid Sequestrants
US20110311621A1 (en) Pharmaceutical compositions and methods of delvery
EP4026566B1 (en) Oral pharmaceutical composition comprising teriparatide and method for preparing same
HK40088265A (en) Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US20240100001A1 (en) Denatonium salt for use in preventing, preventing progression and treating fatty liver diseases
US20250032590A1 (en) Parathyroid hormone compounds in the treatment of hypoparathyroidism
US9198879B2 (en) Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (NDGA)
HK40021032A (en) Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN118055778A (zh) 苦味受体激动剂和肠信号传导化合物的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121121

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121220

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130423

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130917